Calcineurin inhibitor toxicity in a renal transplant recipient.

NDT Plus

Department of Surgery and Transplantation , North Shore University Hospital, Manhasset, NY 11030 , USA.

Published: April 2009

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421359PMC
http://dx.doi.org/10.1093/ndtplus/sfp007DOI Listing

Publication Analysis

Top Keywords

calcineurin inhibitor
4
inhibitor toxicity
4
toxicity renal
4
renal transplant
4
transplant recipient
4
calcineurin
1
toxicity
1
renal
1
transplant
1
recipient
1

Similar Publications

Background: Systemic lupus erythematosus (SLE) is a complex and incurable autoimmune disease, so several drug remission for SLE symptoms have been developed and used at present. However, treatment varies by patient and disease activity, and existing medications for SLE were far from satisfactory. Novel drug targets to be found for SLE therapy are still needed.

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is a chronic, autoimmune inflammatory disease with a multisystem manifestation and a variety of clinical symptoms. Over the last decades, the prognosis and life expectancy of patients with SLE improved significantly due to the implementation of corticosteroids combined with immunosuppressive agents. Nevertheless, the use of these medications is often associated with the occurrence of serious side effects and additional deterioration of organ function.

View Article and Find Full Text PDF

Safety and Efficacy of Infusional Perioperative Tacrolimus Therapy in Crohn's Disease Patients Undergoing Intestinal Resection.

Inflamm Intest Dis

November 2024

Department of Gastroenterology, Endocrinology, Metabolism and Infectiology, University Hospital Marburg, Philipps University Marburg, Marburg, Germany.

Introduction: Perioperative optimization of Crohn's disease (CD) patients is mandatory in order to ensure favorable outcomes and limit perioperative morbidity such as anastomosis-related complications. The use of perioperative tacrolimus may offer beneficial inflammatory control and improve postoperative outcome. However, it also may exhibit unwanted effects of immunosuppression on infectious complications and wound healing.

View Article and Find Full Text PDF

Autoimmune enteropathy (AIE) is a rare immune mediated disorder primarily affecting children, characterized by chronic diarrhea, malabsorption, vomiting, weight loss and villous atrophy. It has also been observed in adults presenting diagnostic and treatment challenges due to its overlap with other gastrointestinal disorders such as celiac disease. Initial diagnostic criteria for AIE include small bowel villous atrophy, lack of response to dietary restrictions, presence of anti-enterocyte antibodies, and predisposition to autoimmunity without severe immunodeficiency.

View Article and Find Full Text PDF

Belatacept was introduced as an immunosuppressant for kidney transplantation in 2010, but its use in Spain remains limited. Since its commercialization, 15 kidney transplant recipients have received immunosuppressive treatment with belatacept at the Cruces University Hospital. This observational and retrospective study analyzes the reasons for switching to belatacept, its impact on kidney function, and the drug's safety profile.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!